The Living Guidelines: UA/NSTEMI Recommendations for Inhibition of the Renin-Angiotensin-Aldosterone System Polling Results for CLASS IIa Guidelines

Any recommendations found on these pages are for education use only. WikiDoc is not a substitute for a licensed healthcare provider. Please see the disclaimers page for important information regarding limitations of the information found here. In suggesting edits to the guidelines, WikiDoc suggests that the following classification scheme be used. Read more about the classification scheme used by the ACC / AHA Guidelines Committee here.

Class IIa Guidelines
1. Angiotensin-converting enzyme inhibitors are reasonable for patients recovering from UA/NSTEMI in the absence of LV dysfunction, hypertension, or diabetes mellitus unless contraindicated. (Level of Evidence: A)

 UA/NSTEMI Guidelines Class IIa Recommendation 1 for Inhibition of the Renin-Angiotensin-Aldosterone System should be: CLASS I CLASS IIa CLASS IIb CLASS III

2. Angiotensin-converting enzyme inhibitors are reasonable for patients with HF and LVEF >40%. (Level of Evidence: A)

 UA/NSTEMI Guidelines Class IIa Recommendation 2 for Inhibition of the Renin-Angiotensin-Aldosterone System should be: CLASS I CLASS IIa CLASS IIb CLASS III

3. In UA/NSTEMI patients who do not tolerate ACE inhibitors, an angiotensin receptor blocker can be useful as an alternative to ACE inhibitors in long term management provided there are either clinical or radiological signs of HF and LVEF <40%. (Level of Evidence: B)

 UA/NSTEMI Guidelines Class IIa Recommendation 3 for Inhibition of the Renin-Angiotensin-Aldosterone System should be: CLASS I CLASS IIa CLASS IIb CLASS III